Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?

No Thumbnail Available

Meeting name

Sponsors

Date

Journal Title

Format

Article

Research Projects

Organizational Units

Journal Issue

Abstract

It's unclear whether disease-modifying antirheumatic agents (DMARDs) as first-line therapy in nonrheumatoid rheumatologic diseases are effective because the question has not been studied. As second-line therapy, the use of some DMARDs appears to be beneficial for patients with psoriatic arthritis (strength of recommendation [SOR: A, based on systematic reviews of good- quality randomized controlled trials) and ankylosing spondylitis (SOR: B, based on systematic reviews of moderate quality trials). Data on the safety and efficacy of DMARDs as second-line therapy for other arthritic conditions is limited (SOR: C, based on small prospective cohort trials).

Table of Contents

DOI

PubMed ID

Degree

Thesis Department

Rights

OpenAccess.

License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.